ProfileGDS5678 / 1452145_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 74% 74% 75% 80% 75% 75% 79% 76% 74% 73% 73% 74% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.862474
GSM967853U87-EV human glioblastoma xenograft - Control 24.8566374
GSM967854U87-EV human glioblastoma xenograft - Control 34.8465274
GSM967855U87-EV human glioblastoma xenograft - Control 45.1503975
GSM967856U87-EV human glioblastoma xenograft - Control 55.6976580
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8619975
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8503275
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4440179
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1438976
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8441974
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.656573
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.688873
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.854674
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6872873